Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2F-high cancers.

Researchers have introduced DiffSMol, a generative AI model capable of generating realistic 3D structures of small molecules ...

INX-315 is an oral, investigational selective cyclin-dependent kinase 2 (CDK2) inhibitor. The designation was based on preclinical data as well as interim data from the ongoing phase 1/2 INX-315-01 ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 5.52%, which has investors questioning if this is right time to buy.

cyclin D1 expression, bone marrow involvement, and other myeloma-defining events — in addition to the persistent excess of lambda light chain on B cells — argued against a diagnosis of IgM ...

India, soon to be the cardiovascular disease capital, faces rising heart attack rates, especially among women who experience ...